Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. 18F-PSMA-1007 Radiotracer Characteristics
3.2. 18F-PSMA-1007 PET/CT Scanning Protocol
3.3. Local Recurrence
3.4. Lymph Node Metastases
3.5. Bone Metastases
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- World Cancer Research Fund International. Prostate Cancer Statistics. Available online: https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/ (accessed on 30 November 2022).
- Wang, L.; Lu, B.; He, M.; Wang, Y.; Wang, Z.; Du, L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health 2022, 10, 811044. [Google Scholar] [CrossRef] [PubMed]
- Bell, K.J.; Del Mar, C.; Wright, G.; Dickinson, J.; Glasziou, P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int. J. Cancer 2015, 137, 1749–1757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinckaers, H.; van Ipenburg, J.; Melamed, J.; De Marzo, A.; Platz, E.A.; van Ginneken, B.; van der Laak, J.; Litjens, G. Predicting biochemical recurrence of prostate cancer with artificial intelligence. Commun. Med. 2022, 2, 64. [Google Scholar] [CrossRef] [PubMed]
- Preisser, F.; Chun, F.K.H.; Pompe, R.S.; Heinze, A.; Salomon, G.; Graefen, M.; Huland, H.; Tilki, D. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. Eur. Urol. 2019, 76, 106–114. [Google Scholar] [CrossRef] [PubMed]
- Alberts, I.L.; Seide, S.E.; Mingels, C.; Bohn, K.P.; Shi, K.; Zacho, H.D.; Rominger, A.; Afshar-Oromieh, A. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: A systematic review and network meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2978–2989. [Google Scholar] [CrossRef]
- Morigi, J.J.; Stricker, P.D.; van Leeuwen, P.J.; Tang, R.; Ho, B.; Nguyen, Q.; Hruby, G.; Fogarty, G.; Jagavkar, R.; Kneebone, A.; et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J. Nucl. Med. 2015, 56, 1185–1190. [Google Scholar] [CrossRef] [Green Version]
- Mingels, C.; Bohn, K.P.; Rominger, A.; Afshar-Oromieh, A.; Alberts, I. Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 2436–2444. [Google Scholar] [CrossRef]
- Rowe, S.P.; Macura, K.J.; Mena, E.; Blackford, A.L.; Nadal, R.; Antonarakis, E.S.; Eisenberger, M.; Carducci, M.; Fan, H.; Dannals, R.F.; et al. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol. Imaging Biol. 2016, 18, 411–419. [Google Scholar] [CrossRef] [Green Version]
- Werner, R.A.; Derlin, T.; Lapa, C.; Sheikbahaei, S.; Higuchi, T.; Giesel, F.L.; Behr, S.; Drzezga, A.; Kimura, H.; Buck, A.K.; et al. 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics 2020, 10, 1–16. [Google Scholar] [CrossRef]
- Tsechelidis, I.; Vrachimis, A. PSMA PET in Imaging Prostate Cancer. Front. Oncol. 2022, 12, 831429. [Google Scholar] [CrossRef]
- Giesel, F.L.; Knorr, K.; Spohn, F.; Will, L.; Maurer, T.; Flechsig, P.; Neels, O.; Schiller, K.; Amaral, H.; Weber, W.A.; et al. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J. Nucl. Med. 2019, 60, 362–368. [Google Scholar] [CrossRef] [Green Version]
- Sprute, K.; Kramer, V.; Koerber, S.A.; Meneses, M.; Fernandez, R.; Soza-Ried, C.; Eiber, M.; Weber, W.A.; Rauscher, I.; Rahbar, K.; et al. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J. Nucl. Med. 2021, 62, 208–213. [Google Scholar] [CrossRef]
- Watabe, T.; Uemura, M.; Soeda, F.; Naka, S.; Ujike, T.; Hatano, K.; Sasaki, H.; Kamiya, T.; Shimosegawa, E.; Kato, H.; et al. High detection rate in [18F]PSMA-1007 PET: Interim results focusing on biochemical recurrence in prostate cancer patients. Ann. Nucl. Med. 2021, 35, 523–528. [Google Scholar] [CrossRef]
- Giesel, F.L.; Hadaschik, B.; Cardinale, J.; Radtke, J.; Vinsensia, M.; Lehnert, W.; Kesch, C.; Tolstov, Y.; Singer, S.; Grabe, N.; et al. F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 678–688. [Google Scholar] [CrossRef] [Green Version]
- Rahbar, K.; Afshar-Oromieh, A.; Jadvar, H.; Ahmadzadehfar, H. PSMA Theranostics: Current Status and Future Directions. Mol. Imaging 2018, 17, 1536012118776068. [Google Scholar] [CrossRef] [Green Version]
- Ghafoor, S.; Burger, I.A.; Vargas, A.H. Multimodality Imaging of Prostate Cancer. J. Nucl. Med. 2019, 60, 1350–1358. [Google Scholar] [CrossRef] [Green Version]
- Oh, S.W.; Cheon, G.J. Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean J. Radiol. 2018, 19, 819–831. [Google Scholar] [CrossRef]
- Czarniecki, M.; Mena, E.; Lindenberg, L.; Cacko, M.; Harmon, S.; Radtke, J.P.; Giesel, F.; Turkbey, B.; Choyke, P.L. Keeping up with the prostate-specific membrane antigens (PSMAs): An introduction to a new class of positron emission tomography (PET) imaging agents. Transl. Androl. Urol. 2018, 7, 831–843. [Google Scholar] [CrossRef]
- Eiber, M.; Fendler, W.P.; Rowe, S.P.; Calais, J.; Hofman, M.S.; Maurer, T.; Schwarzenboeck, S.M.; Kratowchil, C.; Herrmann, K.; Giesel, F.L. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J. Nucl. Med. 2017, 58 (Suppl. 2), 67S–76S. [Google Scholar] [CrossRef] [Green Version]
- Giovacchini, G.; Giovannini, E.; Riondato, M.; Ciarmiello, A. PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. Curr. Radiopharm. 2018, 11, 4–13. [Google Scholar] [CrossRef]
- Ceci, F.; Castellucci, P.; Fanti, S. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Q. J. Nucl. Med. Mol. Imaging 2019, 63, 7–18. [Google Scholar] [CrossRef] [PubMed]
- Treglia, G.; Annunziata, S.; Pizzuto, D.A.; Giovanella, L.; Prior, J.O.; Ceriani, L. Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers 2019, 11, 710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morawitz, J.; Kirchner, J.; Lakes, J.; Bruckmann, N.M.; Mamlins, E.; Hiester, A.; Aissa, J.; Loberg, C.; Schimmöller, L.; Arsov, C.; et al. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. Eur. J. Radiol. 2021, 136, 109556. [Google Scholar] [CrossRef] [PubMed]
- Pianou, N.K.; Stavrou, P.Z.; Vlontzou, E.; Rondogianni, P.; Exarhos, D.N.; Datseris, I.E. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Hell. J. Nucl. Med. 2019, 22, 6–9. [Google Scholar] [CrossRef] [PubMed]
- Anttinen, M.; Ettala, O.; Malaspina, S.; Jambor, I.; Sandell, M.; Kajander, S.; Rinta-Kiikka, I.; Schildt, J.; Saukko, E.; Rautio, P.; et al. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur. Urol. Oncol. 2021, 4, 635–644. [Google Scholar] [CrossRef]
- Dietlein, F.; Kobe, C.; Hohberg, M.; Zlatopolskiy, B.D.; Krapf, P.; Endepols, H.; Täger, P.; Hammes, J.; Heidenreich, A.; Persigehl, T.; et al. Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. J. Nucl. Med. 2020, 61, 729–734. [Google Scholar] [CrossRef] [Green Version]
- Rauscher, I.; Krönke, M.; König, M.; Gafita, A.; Maurer, T.; Horn, T.; Schiller, K.; Weber, W.; Eiber, M. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. J. Nucl. Med. 2020, 61, 51–57. [Google Scholar] [CrossRef]
- Saule, L.; Radzina, M.; Liepa, M.; Roznere, L.; Kalnina, M.; Lioznovs, A.; Mamis, E.; Mikelsone, M.; Biederer, J.; Vjaters, E. Diagnostic scope of 18F-PSMA-1007 PET/CT: Comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence. Am. J. Nucl. Med. Mol. Imaging 2021, 11, 395–405. [Google Scholar]
- Piron, S.; De Man, K.; Van Laeken, N.; D’Asseler, Y.; Bacher, K.; Kersemans, K.; Ost, P.; Decaestecker, K.; Deseyne, P.; Fonteyne, V.; et al. Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer. J. Nucl. Med. 2019, 60, 1736–1742. [Google Scholar] [CrossRef]
- Hofman, M.S.; Hicks, R.J.; Maurer, T.; Eiber, M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics 2018, 38, 200–217. [Google Scholar] [CrossRef] [Green Version]
- Hoffmann, M.A.; von Eyben, F.E.; Fischer, N.; Rosar, F.; Müller-Hübenthal, J.; Buchholz, H.G.; Wieler, H.J.; Schreckenberger, M. Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse. Cancers 2022, 14, 1479. [Google Scholar] [CrossRef]
- Ahmadi Bidakhvidi, N.; Laenen, A.; Jentjens, S.; Deroose, C.M.; Van Laere, K.; De Wever, L.; Mai, C.; Berghen, C.; De Meerleer, G.; Haustermans, K.; et al. Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer. EJNMMI Res. 2021, 11, 41. [Google Scholar] [CrossRef]
- Rahbar, K.; Afshar-Oromieh, A.; Seifert, R.; Wagner, S.; Schäfers, M.; Bögemann, M.; Weckesser, M. Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 2055–2061. [Google Scholar] [CrossRef] [Green Version]
- Sachpekidis, C.; Afshar-Oromieh, A.; Kopka, K.; Strauss, D.S.; Pan, L.; Haberkorn, U.; Dimitrakopoulou-Strauss, A. 18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 592–602. [Google Scholar] [CrossRef]
- Witkowska-Patena, E.; Giżewska, A.; Dziuk, M.; Miśko, J.; Budzyńska, A.; Walęcka-Mazur, A. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. Clin. Nucl. Med. 2019, 44, e629–e633. [Google Scholar] [CrossRef]
- Wondergem, M.; van der Zant, F.M.; Broos, W.A.M.; Knol, R.J.J. Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions. J. Nucl. Med. 2021, 62, 1422–1429. [Google Scholar] [CrossRef]
- Ferrari, M.; Treglia, G. 18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis. Contrast Media Mol. Imaging 2021, 2021, 3502389. [Google Scholar] [CrossRef]
- Lengana, T.; Lawal, I.; Janse Van Rensburg, C.; Mokoala, K.; Moshokoa, E.; Mazibuko, S.; Van de Wiele, C.; Maes, A.; Vorster, M.; Sathekge, M.M. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/mL. Nuklearmedizin 2022, 61, 120–129. [Google Scholar] [CrossRef]
- Kitajima, K.; Suenaga, Y.; Minamikawa, T.; Komori, T.; Otsuki, N.; Nibu, K.; Sasaki, R.; Itoh, T.; Sugimura, K. Clinical significance of SUVmax in (18)F-FDG PET/CT scan for detecting nodal metastases in patients with oral squamous cell carcinoma. Springerplus 2015, 4, 718. [Google Scholar] [CrossRef] [Green Version]
- Chandra, P.; Rajaian, S.; Krishnamurthy, K.; Murugasen, L.; Chandran, G.; Kumar, J.S.; Nath, S. Diagnostic Accuracy of Prebiopsy Ga-68 PSMA PET/CT in Detecting Primary Prostate Carcinomas with Prostate-Specific Antigen <50 ng/mL. Indian J. Nucl. Med. 2020, 35, 283–290. [Google Scholar] [CrossRef]
- Lengana, T.; Lawal, I.O.; Rensburg, C.V.; Mokoala, K.M.G.; Moshokoa, E.; Ridgard, T.; Vorster, M.; Sathekge, M.M. A comparison of the diagnostic performance of 18F-PSMA-1007 and 68GA-PSMA-11 in the same patients presenting with early biochemical recurrence. Hell. J. Nucl. Med. 2021, 24, 178–185. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Wang, Q.; Zhang, B.; Jiang, T.; Zeng, W. Diagnostic accuracy of 18F-PSMA-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis. Hell. J. Nucl. Med. 2022, 25, 88–102. [Google Scholar] [CrossRef] [PubMed]
- De Man, K.; Piron, S.; Van Laeken, N.; Delrue, L.; Fonteyne, V.; Lumen, N.; Van den Broeck, B.; Kersemans, K.; Ost, P.; Schelfhout, V. Impact of 18F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging: 18F-PSMA-11 PET/CT and Impact on Prostate Cancer Management. Mol. Imaging Biol. 2022, 24, 750–758. [Google Scholar] [CrossRef] [PubMed]
- Wang, R.; Shen, G.; Huang, M.; Tian, R. The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer with Biochemical Recurrence: A Meta-Analysis. Front. Oncol. 2021, 11, 684629. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Jiang, T.; Gao, C.; Liu, H.; Sun, Y.; Zou, Q.; Tang, R.; Zeng, W. Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: A systematic review and meta-analysis. Front. Oncol. 2022, 12, 911146. [Google Scholar] [CrossRef] [PubMed]
- Sleeman, J.P.; Thiele, W. Tumor metastasis and the lymphatic vasculature. Int. J. Cancer 2009, 125, 2747–2756. [Google Scholar] [CrossRef] [PubMed]
- Datta, K.; Muders, M.; Zhang, H.; Tindall, D.J. Mechanism of lymph node metastasis in prostate cancer. Future Oncol. 2010, 6, 823–836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mori, S.; Kato, T.; Watabe, T.; Hatano, K.; Abe, T.; Fukuhara, S.; Kiuchi, H.; Imamura, R.; Uemura, M.; Nonomura, N. Oligometastatic Lymph Node Recurrence Detected Using 18F-PSMA-1007 PET/CT in a Patient with Castration-resistant Prostate Cancer After Radiation Therapy. Cancer Diagn. Progn. 2022, 2, 598–602. [Google Scholar] [CrossRef]
- Baas, D.J.H.; Schilham, M.; Hermsen, R.; de Baaij, J.M.S.; Vrijhof, H.J.E.J.; Hoekstra, R.J.; Sedelaar, J.P.M.; Küsters-Vandevelde, H.V.N.; Gotthardt, M.; Wijers, C.H.W.; et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer Prostatic Dis. 2022, 25, 65–70. [Google Scholar] [CrossRef]
- Panagiotidis, E.; Paschali, A.; Giannoula, E.; Chatzipavlidou, V. Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer. Clin. Nucl. Med. 2019, 44, e46–e48. [Google Scholar] [CrossRef]
- EAU Guidelines; EAU: Arnhem, The Netherlands, 2019; ISBN 978-94-92671-04-2.
- Carlos Dos Santos, J.; Beijer, B.; Bauder-Wüst, U.; Schäfer, M.; Leotta, K.; Eder, M.; Benešová, M.; Kleist, C.; Giesel, F.; Kratochwil, C.; et al. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. J. Nucl. Med. 2020, 61, 70–79. [Google Scholar] [CrossRef]
- Radzina, M.; Mamis, E.; Saule, L.; Pajuste, E.; Kalnina, M.; Cocolios, T.; Talip, Z.; Stora, T. Deliverable 5.1—Questionnaire on Industrial and Clinical Key Players and Needs. 2022. Available online: https://zenodo.org/record/7154340#.Y5q9V31ByUk (accessed on 28 October 2022).
Ligand | Chemical Structure |
---|---|
18F-PSMA-1007 | |
68Ga-PSMA-11 | |
18F-JK-PSMA-7 | |
18F-DCFPyL |
Author | Year | Country | Mean Radiotracer Activity | Scanning Scope | Manufacturer of PET/CT | Mean Time Interval between Injection and Image Acquisition (min) |
---|---|---|---|---|---|---|
Mingels et al. [8] | 2022 | Switzerland | 245.7 ± 13.3 MBq | From the head to the thighs | Biograph mCT PET/CT (Siemens, Erlangen, Germany) | 120 ± 10 |
Morawitz et al. [24] | 2021 | Germany | 229 ± 27 MBq | From the skull base to the mid-thigh | Biograph mCT 128 (Siemens Healthineers, Erlangen, Germany) | NM |
Watabe et al. [14] | 2021 | Japan | 259 ± 37 MBq | NM | Discovery 710 (GE, Milwaukee, WI, USA) | 57.7 ± 4.9 |
Hoffmann et al. [32] | 2022 | Germany | NM | Whole body | Gemini TF16 PET/CT scanner (Philips Medical Systems, Best, The Netherlands) | 90 ± 10 |
Giesel et al. [12] | 2019 | Germany, Chile | 301 ± 6.46 MBq | NM | Biograph mCT Flow Scanner (Siemens Medical Solutions) | 92 ± 26 |
Ahmadi Bidakhvid et al. [33] | 2021 | Belgium | 3 MBq/kg | From the vertex to the upper thigh | Discovery MI-4 PET/CT (GE) | 81 ± 16 |
Rauscher et al. [28] | 2020 | Germany | 325 ± 40 MBq | NM | Biograph mCT scanner (Siemens Medical Solutions) | 94 ± 22 |
Dietlein et al. [27] | 2019 | Germany | 159 ± 31 MBq | NM | NM | NM |
Rahbar et al. [34] | 2018 | Germany | 338.02 ± 33.31 MBq | From the lower limbs to the skull | Siemens mCT Scanner (Siemens Healthcare, Knoxville, TN, USA) | Median 120 |
Sachpekidis et al. [35] | 2019 | Germany | Median 237 MBq | From the skull to the fee | Dedicated PET/CT system (Biograph mCT, 128S, Siemens, Erlangen, Germany) | 60 |
Witkowska-Patena et al. [36] | 2019 | Poland | 296 ± 14 MBq | From the top of the head to the mid-thigh | Dedicated hybrid PET/CT system (Discovery 710; GE Healthcare, Chicago, IL, USA) | 95 ± 12 |
Wondergem et al. [37] | 2021 | The Netherlands | 324 MBq | From the skull base to the inguinal region | Biograph-16 TruePoint PET/CT (Siemens Healthcare, Knoxville, TN, USA) | 90 |
Saule et al. [29] | 2021 | Latvia | 363.93 ± 69.40 MBq | From the head to middle thigh | Gemini TF64 (Philips, Koninklijke Philips N.V., Best, The Netherlands) | 54 |
Author | Year | Country | Ligand | Patients (n) | Se | Sp | DR |
---|---|---|---|---|---|---|---|
Hoffmann et al. [32] | 2022 | Germany | 18F-PSMA-1007, 68Ga-PSMA-11 | 128 | - | - | 87.5% |
Liu et al. [43] | 2022 | Meta- analysis | 18F-PSMA-1007 | 799 | 0.836 | 0.946 | - |
De Man et al. [44] | 2022 | Belgium | 18F-PSMA-1007 | 51 | - | - | 82% |
Ferrari et al. [38] | 2021 | Meta- analysis | 18F-PSMA-1007 | 853 | - | - | 81.3% |
Treglia et al. [23] | 2019 | Meta- analysis | 18F-PSMA-1007 | 645 | 81% | ||
Giesel et al. [12] | 2019 | Germany, Chile | 18F-PSMA-1007 | 251 | - | - | 80.2% |
Wang et al. [45] | 2021 | Meta- analysis | 18F-PSMA, 18F-Choline, 18F-Fluciclovine | 1706 | - | - | 83% |
Liu et al. [46] | 2022 | Meta- analysis | 18F-PSMA-1007 | 1002 | - | - | 86% |
Mingels et al. [8] | 2022 | Switzerland | 18F-PSMA-1007 | 177 | 0.95 | 0.89 | - |
Lengana et al. [42] | 2021 | South Africa | 18F-PSMA-1007, 68Ga-PSMA-11 | 21 | 0.889 | 1 | |
Saule et al. [29] | 2021 | Latvia | 18F-PSMA-1007 | 21 | 0.91 | 1 | - |
Watabe et al. [14] | 2021 | Japan | 18F-PSMA-1007 | 28 | - | - | 84.1% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Saule, L.; Radzina, M.; Liepa, M.; Roznere, L.; Lioznovs, A.; Ratniece, M.; Mamis, E.; Vjaters, E. Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State. Diagnostics 2022, 12, 3176. https://doi.org/10.3390/diagnostics12123176
Saule L, Radzina M, Liepa M, Roznere L, Lioznovs A, Ratniece M, Mamis E, Vjaters E. Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State. Diagnostics. 2022; 12(12):3176. https://doi.org/10.3390/diagnostics12123176
Chicago/Turabian StyleSaule, Laura, Maija Radzina, Mara Liepa, Lilita Roznere, Andrejs Lioznovs, Madara Ratniece, Edgars Mamis, and Egils Vjaters. 2022. "Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State" Diagnostics 12, no. 12: 3176. https://doi.org/10.3390/diagnostics12123176